Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer's disease.
BACKGROUND
The recent development of tau-specific positron emission tomography (PET) tracers has allowed in vivo quantification of regional tau deposition and offers the opportunity to monitor the progression of tau pathology along with cognitive impairment. In this study, we investigated the relationships of cerebral tau deposition ([18F]THK5317-PET) and metabolism ([18F]FDG-PET) with concomitant cognitive function in patients with probable Alzheimer's disease (AD).


METHODS
Nine patients diagnosed with AD dementia and 11 with prodromal AD (mild cognitive impairment, amyloid-positive on [11C]PiB-PET) were included in this study. All patients underwent PET scans using each tracer, as well as episodic memory and global cognition assessment. Linear models were used to investigate the association of regional [18F]THK5317 retention and [18F]FDG uptake with cognition. The possible mediating effect of local metabolism on the relationship between tau deposition and cognitive performance was investigated using mediation analyses.


RESULTS
Significant negative associations were found between [18F]THK5317 regional retention, mainly in temporal regions, and both episodic memory and global cognition. Significant positive associations were found between [18F]FDG regional uptake and cognition. The association of [18F]FDG with global cognition was regionally more extensive than that of [18F]THK5317, while the opposite was observed with episodic memory, suggesting that [18F]THK5317 retention might be more sensitive than [18F]FDG regional uptake to early cognitive impairment. Finally, [18F]FDG uptake had a mediating effect on the relationship between [18F]THK5317 retention in temporal regions and global cognition.


CONCLUSIONS
These findings suggest a mediating role for local glucose metabolism in the observed association between in vivo tau deposition and concomitant cognitive impairment in AD.
Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Novum 5th floor, Huddinge, 141 57, Sweden.
Laure
L
Saint-Aubert
Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Novum 5th floor, Huddinge, 141 57, Sweden.|Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden.|Department of Psychology, Stockholm University, Stockholm, Sweden.
Ove
O
Almkvist
Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Novum 5th floor, Huddinge, 141 57, Sweden.
Konstantinos
K
Chiotis
Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Rita
R
Almeida
PET Centre, Uppsala University Hospital, Uppsala, Sweden.|Nuclear medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Anders
A
Wall
Karolinska Institutet, Department NVS, Center for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Novum 5th floor, Huddinge, 141 57, Sweden. agneta.nordbergt@ki.se.|Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden. agneta.nordbergt@ki.se.
Agneta
A
Nordberg
Cognition; Memory; Metabolism; Positron emission tomography (PET); Tau imaging
PLoS One. 2015 Oct 13;10 (10 ):e0140311
26461913
Acta Neuropathol. 2006 Oct;112(4):389-404
16906426
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1686-99
26996778
Trends Neurosci. 2014 Dec;37(12):721-32
25223701
Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1139-50
26572762
Lancet Neurol. 2013 Apr;12(4):357-67
23477989
Neurology. 2012 May 15;78(20):1568-75
22517093
Brain. 1998 Apr;121 ( Pt 4):611-31
9577389
Ann Neurol. 2016 Jan;79(1):110-9
26505746
J Neuropathol Exp Neurol. 2012 May;71(5):362-81
22487856
Neuroimage. 2015 Jan 15;105:357-68
25450107
J Neural Transm Suppl. 1987;24:49-53
3479529
J Neurosci. 2012 Nov 14;32(46):16265-73
23152610
Brain. 2003 Sep;126(Pt 9):1955-67
12821520
Brain. 2006 Nov;129(Pt 11):2856-66
16854944
Lancet Neurol. 2014 Jun;13(6):614-29
24849862
Acta Neuropathol Commun. 2015 Jul 02;3:40
26134112
Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):104-14
22961445
Lancet Neurol. 2010 Jan;9(1):119-28
20083042
Arch Neurol. 1999 Mar;56(3):303-8
10190820
Acta Neuropathol. 1991;82(4):239-59
1759558
Neurology. 2003 May 13;60(9):1495-500
12743238
J Neurosci. 2016 Jan 20;36(3):1001-7
26791227
J Cereb Blood Flow Metab. 1992 Jul;12 (4):571-83
1618936
Front Neurosci. 2015 Nov 04;9:423
26582973
Neurology. 1999 Apr 12;52(6):1158-65
10214737
Brain. 2007 Sep;130(Pt 9):2320-6
17586559
Brain. 2009 Aug;132(Pt 8):2058-67
19477964
Neurobiol Aging. 2009 Apr;30(4):507-14
19231028
Neurobiol Aging. 1997 Jul-Aug;18(4):351-7
9330961
Eur J Neurosci. 2014 Apr;39(7):1202-13
24712999
Lancet Neurol. 2015 Jan;14 (1):114-24
25496902
Eur J Nucl Med Mol Imaging. 2015 Jun;42(7):1052-61
25792456
Brain. 2002 May;125(Pt 5):1116-24
11960900
Neuroimage. 1998 Apr;7(3):176-84
9597659
Brain. 2006 Nov;129(Pt 11):3035-41
17012293
J Nucl Med. 2016 Apr;57(4):574-81
26795290
Brain. 2007 Oct;130(Pt 10):e82
17615094
Lancet Neurol. 2013 Feb;12(2):207-16
23332364
Ann Neurol. 1997 Jan;41(1):17-24
9005861
Neurology. 2004 Mar 23;62(6):925-31
15037694